Last Updated:June 14, 2025, 11:11 IST
Kirti joined Sun Pharma in 1996 and holds a degree in chemical engineering and an MBA.
Dilip Shanghvi (Left) & Kirti Ganorkar (Right)
Who Is Kirti Ganorkar, Sun Pharma New MD? Sun Pharmaceutical Industries Limited announced yesterday that Kirti Ganorkar will be the new Managing Director, effective September 1, 2025. He will succeed Dilip Shanghvi, with the entire business and all functions reporting to him. This appointment is subject to shareholder approval at the upcoming Annual General Meeting.
This announcement is the result of a well-structured and forward-looking succession planning process at Sun Pharma.
Who is Kirti Ganorkar?
Kirti Ganorkar has led Sun Pharma’s India Business since June 1, 2019. Under his leadership, the India Business has grown steadily, increasing its market share. Prior to this role, he held various leadership positions in business development, marketing, mergers and acquisitions, new product introduction, project management, intellectual property, and litigation at Sun Pharma.
He played a crucial role in Sun Pharma’s venture into the specialty sector by securing rights for innovative products like Ilumya. Kirti also spearheaded Sun Pharma’s entry into Japan and laid the initial groundwork for the company’s expansion into Europe. He supported the U.S. business by overseeing several significant generic projects from concept to commercialisation.
Kirti joined Sun Pharma in 1996 and holds a degree in chemical engineering and an MBA.
Kirti Ganorkar, the Managing Director Designate of Sun Pharma, expressed, “It has been an incredibly rewarding experience to be part of the company’s transformation into a leading global pharmaceutical enterprise. Sun Pharma is at an exciting stage with all its businesses well-positioned for growth. Building on the strong foundation laid by Mr Shanghvi and with the support of our global leadership team, I am confident in the continued success of the company.”
Dilip Shanghvi, Chairman and Managing Director of Sun Pharma, said, “Kirti has consistently shown effective leadership in managing diverse roles at Sun. I firmly believe in his ability to lead the company into its next growth phase and extend my best wishes for his success. Kirti’s elevation highlights our strong in-house talent pool, ensuring continuity of Sun’s core value systems.”
As Executive Chairman, Mr. Shanghvi will continue to chair the Board. He will focus on strengthening Sun Pharma’s specialty portfolio and provide insights towards shaping the company’s long-term strategy.
A team of writers and reporters decodes vast terms of personal finance and making money matters simpler for you. From latest initial public offerings (IPOs) in the market to best investment options, we cover al…Read More
A team of writers and reporters decodes vast terms of personal finance and making money matters simpler for you. From latest initial public offerings (IPOs) in the market to best investment options, we cover al… Read More
- First Published:
#Kirti #Ganorkar #Meet #Successor #Sun #Pharma #Chief #Dilip #Shanghvi
